1Ochi S, Kawasoe K, Abe M, Fukuhara R, Sonobe K, Kawabe K, et al. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Gen Hasp Psychiatry 2011; 33(6): 640.e1-640.e2.
2Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neurolept-ic, haloperidol, in the treatment of psychoses. Ann Med Psychol (Paris) 1960; 118(I): 145-152.
3Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164(6): 870-876.
4Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmaco12009; 19(4): 415-422.
5American Psychiatric Association. DSM-IV, International Version with ICD-10 codes. Washington D.C.: American Psychiatric Press, 1995: 757-760.
6Yin MS. Possible cases of malignant syndrome in 10 patients. Foreign Medical Science: Section of Psychiatry 1989; 3:169. (in Chinese).
7Chandran G J, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003; 3.69 (5): 439 -444.
8Zivkovi( M, Mihaljevk-Peles A, Sagud M, Sili(A, Mihanovi M. The role of CYP2D6 and Taql A polymorphisms in malignant neurolept-ic syndrome: two case reports with three episodes. Psychiatr Danub 2010; Z2(1): 112-116.
9Wang Y. Risk factors and pathogenesis of neurolept-ic malignant syndrome. Medical Journal of Chinese People's Health 2021; 23(15): 1905-1096,1920. (in Chinese).
10Langan J, Mart-in D, Shajahan P, Smith DJ. Antipsychot-ic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report. BMC Psychiatry 2022; 12: 224.
